Luffa

Luffa

Identity, Taxonomy, and Natural Source

Luffa is a genus of tropical and subtropical annual climbing vines belonging to the family Cucurbitaceae, which also includes cucumbers, pumpkins, and snake gourds. The genus Luffa (Linn.) encompasses a group of gourds also known as vegetable sponges, dishcloth gourds, running okra, strainer vine, Chinese okra, California okra, and loofah. Two species are most commonly distinguished: the angled luffa (Luffa acutangula) and the smooth-fruited version, Luffa cylindrica or Luffa aegyptiaca. A third species, Luffa operculata, is botanically and pharmacologically distinct from the smooth-fruited species and receives separate attention in this article.

Luffa aegyptiaca, the sponge gourd, Egyptian cucumber, or Vietnamese luffa, is an annual species of vine cultivated for its fruit, native to South and Southeast Asia. The synonymous botanical specific epithet "aegyptiaca" was given to the plant in the 16th century when European botanists were introduced to it through its cultivation in Egypt. In European botanical literature, the plant was first described by Johann Veslingius in 1638, who named it "Egyptian cucumber." Veslingius also introduced the name "Luffa."

The synonymy of the smooth-fruited species is considerable. Luffa cylindrica (L.) M.J. Roem. is widely used in scientific literature, while Luffa aegyptiaca Mill. is considered the preferred nomenclature in some taxonomic authorities. Additional synonyms recorded in the literature include Momordica cylindrica L. and Momordica luffa L. The plant is a subtropical vegetable and widely cultivated in tropics and subtropics in Asia, India, Brazil, and the USA.

Luffa cylindrica, popularly known as sponge gourd, is a tropical and sub-tropical fibrous plant with fruits containing black seeds. The fruit is consumed by humans as a vegetable in many parts of Asia, while different parts of the plant are used for cosmetics and as medicine in many parts of the globe.

Morphology

Luffa is a large climber with a stout, five-angled pubescent stem with tendrils that are usually two to three branched. The leaves are large, 10–20 cm long and 9–21 cm wide. The fruit is approximately 30 cm long and, maturing to brown, resembles a cucumber in shape and size. It grows as a flowering annual vine with pollinated flowers developing into cylindrical green fruits filled with seeds in a system of many intertwined cellulose fibres.

Common Names and Forms of Preparation

Luffa is known by a wide array of names reflecting its geographic spread: sponge gourd, loofah, vegetable sponge, dishcloth gourd, and — in Traditional Korean Medicine — simply as loofa or luffa sponge. It is a vigorous annual climbing plant. This plant is the major source of the loofah sponge or skin brush, widely used for cleaning the body. The plant is also sometimes used for food and has a range of traditional medicinal uses.

Common preparations include:

• Dried fibrous sponge: The vascular network of mature fruits, dried and used as a body scrub, cosmetic tool, or filtration material.
• Aqueous and ethanol plant extracts: Made from fruit pulp, peel, leaves, seeds, and roots; used in experimental pharmacological research.
• Decoctions and infusions: Used in traditional and folk medicine preparations from the fruit, leaf, and seed.
• Homeopathic preparations: Highly diluted preparations of Luffa operculata (a related South American species) used in nasal sprays and tablets for sinusitis and allergic rhinitis.
• Seed oil: Cold-pressed or solvent-extracted from seeds; investigated for its lipid composition and bioactive content.

Traditional and Historical Use

Asia

Historically integrated into the diets of communities in Vietnam, India, and Egypt, the luffa has been a staple in traditional cuisines and medicine for centuries. Its mention in ancient Ayurvedic texts highlights its longstanding medicinal and dietary significance.

In Traditional Chinese Medicine (TCM), luffa — referred to as "si gua lou" — was often used to clear heat and phlegm, benefiting conditions such as bronchitis, sinus congestion, and persistent coughs. The dried fruit was incorporated into decoctions to soothe sore throats, remove toxins, and expel mucus.

The fruit pulp of Luffa cylindrica has been used to promote menstruation, hemostasis, resolve phlegm, invigorate the network vessels, clear fever, and invigorate blood in traditional Korean medicine.

A brand of curry produced from the fruit — stripped, chopped, and fried — is prepared in China and India. The fruit is also consumed fresh or diced and processed in Japan for later consumption. Different parts of Luffa acutangula (the angled luffa) have been used extensively by different ethnic groups in India for medicinal purposes. In Maharashtra and the tribal areas of Madhya Pradesh, leaves and fruit powder are used for the treatment of jaundice.

Africa

Leaves are ground with water and the juice is used for stomach upset medication in Rwanda. Leaf decoctions are used to ease childbearing in Uganda. Pulverized leaves are anally inserted for enterobiasis therapy in the Central African Republic. A decoction of the leaves is used against filaria and a colloidal solution of fresh leaves is used to combat whooping cough in Congo-Brazaville. Root formulation is used in Gabon as a medicine for nose cancer. The seed is used in Egypt for managing diabetes.

An ethnobotanical survey has also documented its use to protect against jaundice, insect bites, swollen hemorrhoids, dysentery, and headache.

Broad Traditional Indication Profile

Luffa cylindrica was used traditionally for the treatment of asthma, intestinal worms, sinusitis, chronic bronchitis pain, carbuncles, abscesses, inflammation, heat rashes of children in summer, bowel or bladder hemorrhage, hemorrhoids, jaundice, menorrhagia, haematuria, leprosy, and spleenopathy, as well as functioning as an anthelmintic, carminative, emmenagogue, galactagogue, and antiseptic.

The plant has been used in the treatment of many ailments including nose cancer, snake venom, wound healing, edema, enterobiasis, filaria, whooping cough, stomach upset, stomach pain, and malaria.

Luffa operculata in South American Tradition

Luffa operculata, known in Brazil as buchinha-do-norte or cabacinha, is the most widely recalled and used medicinal plant by the Brazilian population to treat rhinitis and rhinosinusitis. Despite the lack of scientific evidence about its use, most ENT physicians know of its effects and receive many patients who had used the plant, sometimes presenting adverse reactions such as epistaxis, nasal irritation, and olfaction disturbances.

Key Constituents and Active Compounds

Primary Phytochemical Classes

Phytochemical screening of Luffa cylindrica revealed that the plant contained anthocyanins, glycosides, flavonoids, triterpenoids, cardiac glycosides, saponins, carbohydrates, proteins, alkaloids, and tannins. Aqueous extract screening of Luffa aegyptiaca showed positive results for flavonoids, saponins, tannins, and cardiac glycoside compounds.

Specific Identified Compounds

Many health-promoting compounds have been detected or isolated from different parts of the plant, including flavonoids (apigenin-7-glucuronide, luteolin-7-O-β-D-glucuronide methyl ester, luteolin-7-O-β-D-glucuronide methyl ester), phenolic acids (p-coumaric, gallic, caffeic, chlorogenic), triterpenoids (oleanolic acid and echinocystic acid), saponins (lucyoside AM), tannins (catechin), ribosome-inactivating proteins (α-luffin), carotenoids (9-cis neoxanthin, all-trans-lutein, all-trans-β-carotene), chlorophylls (chlorophyll a and b, pheophytin), cucurbitacin B, and gypsogenin.

Phenolics and flavonoids are present in abundant amounts in the aqueous extract of the fruit peel, while in the ethyl acetate peel extract, oleanolic acid, carotenoids, and chlorophylls dominate.

In seed oil, sitosterol, beta-tocopherol, phytol, stigmasterol, and hydrocarbons have been identified in the unsaponifiable fraction. Glycolipids, such as monogalactosyldiacylglycerol, digalactosyl diacylglycerol, and digalactosyl monoacyl glycerol, were found in the seed oil. Phosphatidylethanolamine was the dominant phospholipid in this oil.

Ribosome-Inactivating Proteins (RIPs) — The Luffin Family

A distinctive class of compounds found in Luffa seeds is the luffins — a family of ribosome-inactivating proteins (RIPs). A novel RIP designated Luffin-S was purified and characterized from the seeds of Luffa cylindrica. Unlike Luffin-A and B — which are RNA N-glycosidases with molecular weights of 27 and 28 kDa respectively — Luffin-S has a molecular weight of approximately 10 kDa, making it smaller than any other RIPs previously investigated. Its toxicity is similar to trichosanthin in a cell-free protein synthesis system, and its unique mechanism as a phosphodiesterase marks it as a potential toxic moiety for immunotoxin development.

A peptide designated Luffin P1 was purified from the seeds of Luffa cylindrica. Its molecular mass was determined to be 5,226.1 Da by MALDI-TOF MS analysis. The purified Luffin P1 shows strong inhibitory activity on protein synthesis in a cell-free rabbit reticulocyte lysate with an IC₅₀ of 0.88 nM. Its reaction mechanism is the same as that of the ribosome-inactivating protein trichosanthin, which is an rRNA N-glycosidase.

Luffin-a, a single-chain Type I ribosome-inactivating protein, is known to be the most toxic of the luffin family and apparently possesses antitumor activity; it was isolated from Luffa cylindrica seeds.

Cucurbitacins (particularly in Luffa operculata)

Luffa operculata contains several bioactive compounds, primarily cucurbitacins such as cucurbitacin B, which are tetracyclic triterpenes exhibiting anti-inflammatory and antimicrobial properties; these are most abundant in the fruits and seeds, alongside flavonoids, saponins, glycosides, and phenolic compounds. The active ingredient isocucurbitacin B reportedly presents biological activities including decongestant actions as well as laxative, hemolytic, embryotoxic, and abortion-inductive properties.

Mechanisms of Action

Anti-Inflammatory Mechanisms

Both ethanol and ethyl acetate extracts of Luffa cylindrica peel and pulp decreased production of nitric oxide in LPS-induced RAW 264.7 macrophage cells, while the ethanol extract mitigated secretion of prostaglandin E₂. Furthermore, all the extracts significantly inhibited IL-6 production, but remained ineffective in retarding generation of IL-1β and TNF-α.

It has been reported that ethanol and ethyl acetate extracts of L. cylindrica inhibit the inflammatory response through inhibiting production of inflammatory mediators, including nitric oxide (NO), prostaglandin E₂ (PGE₂), and pro-inflammatory cytokine IL-6 in murine macrophage cell lines.

Antidiabetic and Hypoglycemic Mechanisms

The proposed mechanism of action of Luffa cylindrica (sponge gourd) extract in animal models is that it increases insulin secretion from β-cells of the islets of Langerhans in the pancreas. The hypoglycemic behavior of Luffa cylindrica extract compared to glibenclamide suggests that their modes of action are likely to be similar. Plants with high flavonoid content have been shown to have hypoglycemic and antidiabetic properties, and investigation indicates that L. cylindrica peel extract is rich in flavonoids and phenolic compounds.

Ribosome-Inactivating / Antitumor Mechanism

Recombinant alpha-luffin could inhibit protein synthesis in the rabbit reticulocyte lysate system. It inhibited the growth of tumor cell lines in a dose- and time-dependent manner. Additionally, recombinant alpha-luffin was able to induce cell death by apoptosis. The cytotoxicity of alpha-luffin towards tumor cells makes it a potential antitumor agent.

Mucociliary Mechanism (Luffa operculata)

Pharmacological studies in animal and ex vivo models have demonstrated mucolytic and expectorant-like effects, with extracts reducing mucociliary transport velocity and ciliary beat frequency in the isolated frog palate — potentially aiding mucus clearance at low doses but inhibiting it at high doses.

Scientific Evidence by Area of Use

1. Inflammation and Atopic Dermatitis

Evidence level: Preclinical (in vitro and animal models only; no published human clinical trials).

The fruit pulp of Luffa cylindrica has been used to induce hemostasis, resolve phlegm, and clear fever in traditional Korean medicine; however, the efficacy of L. cylindrica had not been examined in atopic dermatitis. A 70% ethanol extract of L. cylindrica was therefore evaluated to determine anti-inflammation and anti-atopic dermatitis effects in vitro and in vivo.

Luffa cylindrica extract (10 mg/mouse/day) was topically applied to the dorsal skin and ears of Dermatophagoides farinae-sensitized Nc/Nga mice for 4 weeks. The IC₅₀ values of L. cylindrica extract on PGE₂ and histamine production were 16.89 and 139.9 mg/mL. The production of atopic dermatitis-related chemokines (TARC and RANTES) were inhibited 20% and 12% by L. cylindrica extract (50 mg/mL) in HaCaT cells respectively (p < 0.05). In sensitized Nc/Nga mice, plasma levels of IgE and histamine were suppressed 36% and 41% by L. cylindrica extract, respectively (p < 0.05).

A separate in vitro and in silico study on oral carcinoma cells found that L. cylindrica peel extract exhibits potent antioxidant and anti-inflammatory activities, likely due to its phytochemical profile. The interaction of beta-carotene, a compound from the extract, with apoptotic proteins supports its potential role in anticancer activity. These findings are preliminary and have not been validated in human subjects.

2. Antioxidant Activity

Evidence level: Preclinical (in vitro only).

Crude ethanol and ethyl acetate leaf extracts of L. cylindrica showed average antioxidant properties at 100 µg/mL, with inhibitions of 53.31% and 54.73% respectively in DPPH radical scavenging assays. These results demonstrate antioxidant capacity in laboratory conditions, but have not been confirmed in human trials.

3. Antimicrobial Activity

Evidence level: Preclinical (in vitro only).

In antimicrobial evaluation, ethanol and ethyl acetate leaf extracts of L. cylindrica showed moderate antibacterial activity against S. aureus, S. Typhi, and B. subtilis. The ethyl acetate extract exhibited considerable antimicrobial activity against the test isolates compared to the ethanol extract.

For Luffa operculata specifically, the aqueous extract presented a predominance of 2,3-dicaffeoylglyceric acid. There was a significant difference in bacterial growth of Streptococcus pyogenes on blood-agar plates when under the influence of both the aqueous extract and the active substance. No human clinical studies have assessed antimicrobial efficacy.

4. Hypoglycemic / Antidiabetic Effects

Evidence level: Preclinical animal studies only; no human clinical trials identified.

Methanol extract of Luffa cylindrica exhibited significant anti-hyperglycemic activity in alloxan-induced diabetic rats. Acute toxicity studies indicated a high safety margin with no observed mortality at 3,000 mg/kg.

The methanol extract significantly reduced blood glucose levels in diabetic rats, with treatments showing comparable effects to glibenclamide at doses of 200 and 400 mg/kg after 15 days. One study reported the plant extract attenuated blood glucose levels from 300.47 mg/dL to 142.40 mg/dL — a 53.92% reduction — after 21 days of administration. Similar glucose-lowering results were observed when Luffa cylindrica fruit extract was given to alloxan-induced diabetic rats, though neither the key phytochemical responsible nor the precise mechanism of hypoglycemic activity were fully elucidated.

5. Hepatoprotective Effects

Evidence level: Preclinical animal studies only.

Luffa cylindrica commonly called sponge gourd has both medicinal and nutritional properties. It is used traditionally for the management of liver diseases. Researchers investigated the hepatoprotective effect of the crude methanol extract of L. cylindrica fruit in rats chronically exposed to carbon tetrachloride (CCl₄). Male rats were exposed to CCl₄ twice a week for six weeks and the extract was administered five times a week for six weeks.

A separate study examining serum biochemical indices reported that hepatic function indices such as Alanine Transaminase (ALT), Aspartate Transaminase (AST), and Alkaline Phosphatase (ALP) were reduced in a non-significant manner across all treatment groups. Total protein and albumin levels increased in extract-treated rats but these changes were not significantly different from the negative control. All bilirubin values were not significantly different from the negative control. These results suggest that Luffa cylindrica does not induce hepatotoxicity at the tested doses of 100, 200, and 400 mg/kg orally.

6. Antitumor / Anticancer Activity

Evidence level: In vitro and laboratory (no human clinical trials).

Research on luffin proteins has identified their cytotoxic potential against cancer cell lines. One study describes the liposome-mediated delivery of the type I ribosome-inactivating protein luffin to human melanoma cells in vitro. Luffin from Luffa cylindrica seeds was incorporated into lecithin/cholesterol liposomes. Exposure of melanoma cells to these liposomes resulted in the inhibition of protein synthesis and cell growth; apoptotic cell death was verified by TUNEL reaction and quantitation of cytosolic oligonucleosome-bound DNA. The toxicity of encapsulated luffin varied with the lipid composition of the vesicles; the strongest effect was observed with lecithin/cholesterol liposomes. These results identified liposome-incorporated luffin as a possible alternative to immunotoxins for the treatment of human melanoma in situ.

α-Luffin, found in Luffa cylindrica seeds, is a type I ribosome-inactivating protein. Cytotoxic effects make it an appropriate candidate for the construction of immunotoxins and conjugates. All findings to date are from in vitro or animal experiments, and no clinical trials in humans have been reported.

7. Anthelmintic Activity

Evidence level: Preclinical in vitro only.

Various extracts (50 and 100 mg/mL) of Luffa cylindrica were tested for anthelmintic activity against the Indian earthworm Pheretima posthuma, in terms of time for paralysis and time for death of worms. The results revealed that the methanol and aqueous extracts possessed anthelmintic activity at a concentration of 100 mg/mL. These findings cannot be extrapolated to human helminth infections without clinical evidence.

8. Sinusitis and Allergic Rhinitis (Luffa operculata)

Evidence level: Limited human clinical data, primarily open-label or with methodological limitations; one randomized controlled trial found no advantage over placebo.

The efficacy and safety of a fixed-combination homeopathic medication (Sinusitis PMD) consisting of Lobaria pulmonaria, Luffa operculata, and potassium dichromate were investigated in an open-label, practice-based study of 119 male and female patients, aged 12 to 57 years, with clinical signs of acute sinusitis not previously treated. At the first visit, after a mean of 4.1 days of treatment, secretolysis had increased significantly and typical sinusitis symptoms — such as headache, pressure pain at nerve exit points, and irritating cough — were reduced. Ninety-nine patients received only the test medication. This study was open-label and uncontrolled, which significantly limits its interpretive value.

In contrast, a randomized, controlled, double-blind trial assessed homeopathic preparations of L. operculata for sinusitis directly. A controlled randomized double-blind trial carried out by 47 physicians in private practice with 152 patients with sinusitis investigated several homeopathic drug preparations: Group A received a combination of Luffa operculata D4, kalium bichromicum D4, and cinnabaris D3; Group B received a combination of kalium bichromicum D4 and cinnabaris D3; Group C received Luffa operculata D4 alone; and Group D received placebo. Criteria for therapeutic result included headache, blocked nasal breathing, trigeminal tenderness, reddening and swelling of nasal mucosa, and postnasal secretion. There was no remarkable difference in therapeutic success among the investigated homeopathic drug combinations, nor between the active drugs and placebo. Averaged over all four groups, 81% of patients with acute sinusitis and 67% of patients with chronic sinusitis recovered. This finding suggests the observed improvements may reflect natural disease resolution rather than a drug-specific effect.

A nasal spray product (Luffa comp.-Heel) combining Luffa with other homeopathic ingredients was evaluated in a randomized equivalence trial for seasonal allergic rhinitis. Early research suggests that using a homeopathic nasal spray containing luffa and other ingredients for 6 weeks might help control seasonal allergy symptoms. However, the multi-ingredient nature of these preparations makes it impossible to attribute any observed effect specifically to Luffa operculata.

A preclinical study in a bacterial rhinosinusitis animal model found that intranasal treatment of sinusitis with L. operculata showed better clinical evolution than the control group. A statistically significant difference between the treated group and the control group was observed in histologic evaluation for inflammatory pattern.

Body Systems and Health Areas Associated with Luffa

• Respiratory system: Traditional use in asthma, bronchitis, cough, sinusitis, and rhinitis; Luffa operculata used in nasal preparations.
• Gastrointestinal system: Traditional use for stomach upset, worm infestations, acid reflux, constipation, and dysentery.
• Hepatic system: Traditional use for jaundice; preclinical evidence of hepatoprotection in CCl₄-induced liver injury models in rats.
• Endocrine/metabolic system: Preclinical evidence of blood glucose reduction in diabetic animal models; traditional use in diabetes management.
• Skin and integumentary system: Traditional use for heat rash, leprosy, wound healing, carbuncles; preclinical evidence in atopic dermatitis models; topical use of the fibrous sponge for exfoliation.
• Immune system: Modulation of IgE, histamine, and cytokines documented in preclinical models.
• Reproductive system: Traditional emmenagogue use; abortifacient properties documented for certain species, particularly L. operculata.
• Cancer biology (research context only): In vitro cytotoxicity of luffin proteins against cancer cell lines.

Dosage Forms and Reported Study Dosages

No standardized therapeutic dosage has been established for any indication through human clinical trials. The following dosages appear strictly as reported in preclinical source literature and should not be interpreted as recommended human doses.

• Luffa cylindrica extract (10 mg/mouse/day) was topically applied to the dorsal skin and ears of sensitized Nc/Nga mice for 4 weeks in an atopic dermatitis model.
• The methanol extract was given at doses of 200 and 400 mg/kg in diabetic rats, showing effects comparable to glibenclamide after 15 days.
• In a serum biochemical study, leaf extract was given at doses of 100, 200, and 400 mg/kg orally.
• In the Luffa operculata toxicity study, rats received 1.0 mg/kg per day of the extract orally for five consecutive days.
• In an anti-inflammatory evaluation, the ethanol leaf extract of L. cylindrica was given at 50 mg/kg, producing an inhibition of 31.1%, compared to 39.7% for diclofenac.
• For anthelmintic activity, various extracts were tested at concentrations of 50 and 100 mg/mL against Pheretima posthuma.

Safety Considerations

General Oral and Topical Use of Luffa cylindrica

Acute toxicity studies of methanol extract of Luffa cylindrica indicated a high safety margin with no observed mortality at 3,000 mg/kg in rodent models. A rat study suggested that Luffa cylindrica does not induce hepatotoxicity at tested doses of 100, 200, and 400 mg/kg orally. No systematic human safety data are available.

Luffa operculata: A Distinct and More Hazardous Species

Luffa operculata products have a wide range of pharmacological activities in vitro, ex vivo, and in vivo, but the toxicological spectrum is also alarming, encompassing cytogenotoxicity, tissue toxicity, (sub-)acute toxicity, reproductive toxicity, neurotoxicity, and phytotoxicity.

Luffa operculata infusion in currently used doses can promote significant structural and ultrastructural changes — including enlargement of intercellular spaces and tight junction disruption — in the epithelium of an ex vivo model of respiratory mucosa.

Cucurbitacin B, a primary active constituent of L. operculata, is known for its acute toxicity when ingested and is classified as category 2 according to the Globally Harmonized System of Classification.

Luffa should not be used in pregnancy; certain luffa species have been associated with abortifacient activity. This concern applies particularly to L. operculata: dried fruits of Luffa operculata are abortifacient and showed undesirable effects in male and female adult Wistar rats. Animal research has documented testicular damage: morphological studies in male testis showed changes in the parenchyma and lumen, alterations in the diameter of seminiferous tubules, and a decrease in Leydig cell numbers.

There is evidence of cytogenotoxicity, tissue toxicity, (sub-)acute toxicity, reproductive toxicity, neurotoxicity, and phytotoxicity. Toxicological data (in vitro, ex vivo, and in vivo) warn of caution in the use of L. operculata.

Despite the plant's widespread popular use for rhinitis and rhinosinusitis, adverse reactions observed and reported by ENT physicians include epistaxis, nasal irritation, and olfactory disturbances.

A historical reference attests to its purgative properties and adverse events attributed to its use since at least the 1840s.

Regulatory Status

In Brazil, Luffa operculata extracts are overseen by the Agência Nacional de Vigilância Sanitária (ANVISA) as phytotherapeutic agents for traditional nasal applications, with commercial products required to meet safety standards; however, due to reported toxicity risks, their use is cautioned with emphasis on monitoring. No major regulatory body (EMA, FDA, or WHO) has issued a positive monograph endorsing the therapeutic use of any Luffa species.

Overall Evidence Characterization

Extracts of the plant and isolated compounds have demonstrated wide-spectrum pharmacological activities and have been shown to possess antiemetic, antidiabetic, antiviral, wound healing, anticancer, antipyretic, anti-inflammatory, antifungal, antibacterial, anthelmintic, hypoglycemic and antihyperglycemic, antioxidant, and hepatoprotective effects in animal models. Nonetheless, virtually all of this evidence originates from preclinical studies (cell culture experiments and animal models). Rigorous, placebo-controlled human clinical trials establishing efficacy and safe dosing parameters for any indication have not been conducted for Luffa cylindrica. For Luffa operculata, limited human-use data exists from open-label studies of combination homeopathic products, while a randomized double-blind trial in sinusitis found no advantage over placebo. The full toxicological implications of therapeutic use across all species of Luffa in humans remain incompletely characterized.

References

• ScienceDirect Topics: Luffa aegyptiaca — an overview
• ScienceDirect Topics: Luffa — an overview
• Wikipedia: Luffa aegyptiaca
• IntechOpen: A Review on the Ethnobotanical Uses, Phytochemistry and Pharmacological Effect of Luffa cylindrica
• Plants Journal: Traditional and medicinal uses of Luffa cylindrica: a Review
• Frontiers in Pharmacology: Therapeutic Potential of Luffa acutangula (Shendge & Belemkar, 2018)
• PubMed: Therapeutic Potential of Luffa acutangula — Review (PMID 30459601)
• PubMed: Functional components in Luffa cylindrica and their effects on anti-inflammation of macrophage cells (PMID 22868104)
• PubMed: Luffa cylindrica suppresses development of Dermatophagoides farinae-induced atopic dermatitis-like skin lesions in Nc/Nga mice (PMID 25327534)
• PMC: Luffa cylindrica suppresses development of atopic dermatitis-like skin lesions (PMC4364561)
• PubMed: Phytochemical Studies, Antioxidant Potential, and GC-MS of Luffa cylindrica (L.) Fruit (PMID 35583705)
• PubMed: Two proteins with ribosome-inactivating, cytotoxic and abortifacient activities from seeds of Luffa cylindrica (PMID 1503559)
• PubMed: Purification and characterization of Luffin P1, a ribosome-inactivating peptide from seeds of Luffa cylindrica (PMID 12948831)
• PubMed: Luffin-S — a small novel ribosome-inactivating protein from Luffa cylindrica (PMID 8034014)
• PubMed: Cloning and soluble expression of mature alpha-luffin from Luffa cylindrica and its antitumor activities in vitro (PMID 20705600)
• ScienceDirect: Antiproliferative effect and apoptotic response of human melanoma cells to liposomes containing luffin
• IJPSR: Antidiabetic, Antihyperlipidemic, Antioxidant, Hepatoprotective and Renal Protective Effect of Luffa cylindrica Extract in Streptozotocin-Induced Diabetic Rats
• Journal of Health Sciences: Evaluation of Antioxidant, Anti-inflammatory and Antimicrobial Activities of Leaf Extracts of Luffa cylindrica
• PubMed: Efficacy and safety of a fixed-combination homeopathic therapy for sinusitis (PMID 10539378)
• PMC: Preclinical evaluation of Luffa operculata Cogn. and its main active principle in the treatment of bacterial rhinosinusitis (PMC9442899)
• ScienceDirect: Preclinical evaluation of Luffa operculata Cogn. and its main active principle in the treatment of bacterial rhinosinusitis
• PMC: Luffa operculata effects on the epithelium of frog palate: histological features (PMC9450526)
• ScienceDirect: Pharmacology, toxicology and homeopathy of Luffa operculata (L.) Cogniaux (Cucurbitaceae): Integrative review
• ScienceDirect: Luffa operculata fruit aqueous extract induces motor impairments, anxiety-like behavior, and testis damage in rats
• ResearchGate: Evaluation of hypoglycemic and antihyperglycemic effects of Luffa cylindrica fruit extract in rats
• Science Publishing Group: Effects of Aqueous-Methanol Leaf Extract of Luffa cylindrica on Serum Biochemical Indices of Wistar Rats
• ResearchGate: Constituents and pharmacology of Luffa cylindrica — A review
• IOSR Journal of Pharmacy: Constituents and pharmacology of Luffa cylindrica — A review
• IJSRST: Preliminary Qualitative Phytochemical Profiling of Luffa Aegyptiaca
• Journal of Contemporary Dental Practice: Phytochemical Screening, Antioxidant, and Anti-inflammatory Activity of Luffa cylindrica Extract in Oral Carcinoma (2025)